External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.

Several prediction models have been developed to estimate the outcomes of prostate biopsies. Most of these tools were designed for use with Western populations and have not been validated across different ethnic groups. Therefore, we evaluated the predictive value of the Prostate Cancer Prevention Trial (PCPT) and the European Randomized Study of Screening for Prostate Cancer (ERSPC) risk calculators in a Chinese cohort. Clinicopathological information was obtained from 495 Chinese men who had undergone extended prostate biopsies between January 2009 and March 2011. The estimated probabilities of prostate cancer and high-grade disease (Gleason >6) were calculated using the PCPT and ERSPC risk calculators. Overall measures, discrimination, calibration and clinical usefulness were assessed for the model evaluation. Of these patients, 28.7% were diagnosed with prostate cancer and 19.4% had high-grade disease. Compared to the PCPT model and the prostate-specific antigen (PSA) threshold of 4 ng ml(-1), the ERSPC risk calculator exhibited better discriminative ability for predicting positive biopsies and high-grade disease (the area under the curve was 0.831 and 0.852, respectively, P<0.01 for both). Decision curve analysis also suggested the favourable clinical utility of the ERSPC calculator in the validation dataset. Both prediction models demonstrated miscalibration: the risk of prostate cancer and high-grade disease was overestimated by approximately 20% for a wide range of predicted probabilities. In conclusion, the ERSPC risk calculator outperformed both the PCPT model and the PSA threshold of 4 ng ml(-1) in predicting prostate cancer and high-grade disease in Chinese patients. However, the prediction tools derived from Western men significantly overestimated the probability of prostate cancer and high-grade disease compared to the outcomes of biopsies in a Chinese cohort.

[1]  Donna P Ankerst,et al.  Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. , 2009, The Journal of urology.

[2]  N. Breslow,et al.  Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France , 1977, International journal of cancer.

[3]  N. Keating,et al.  Explaining racial differences in prostate cancer mortality , 2012, Cancer.

[4]  G. Stemmermann,et al.  Geographic pathology of latent prostatic carcinoma , 1982, International journal of cancer.

[5]  R. Shinghal,et al.  Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes. , 2008, The Journal of urology.

[6]  S. Bigler,et al.  Prostate cancer detection in Black and White men with abnormal digital rectal examination and prostate specific antigen less then 4 ng./ml. , 2000, The Journal of urology.

[7]  Frederico Branco,et al.  Prostate cancer prevention trial and European randomized study of screening for prostate cancer risk calculators: a performance comparison in a contemporary screened cohort. , 2010, European urology.

[8]  William J Catalona,et al.  Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. , 2003, The New England journal of medicine.

[9]  Ewout W Steyerberg,et al.  A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. , 2010, European urology.

[10]  E. Crawford,et al.  Prostate-specific antigen (PSA) screening: has the pendulum swung too far? , 2011, Asian journal of andrology.

[11]  X. Yao,et al.  Prevalence of incidental prostate cancer in patients undergoing radical cystoprostatectomy: data from China and other Asian countries. , 2009, Asian journal of andrology.

[12]  P. Walsh,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.

[13]  Bao-xue Yang,et al.  Prostate cancer: an emerging threat to the health of aging men in Asia. , 2011, Asian journal of andrology.

[14]  Moon S. Chen,et al.  Cancer Incidence, Mortality, and Associated Risk Factors Among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese Ethnicities , 2007, CA: a cancer journal for clinicians.

[15]  E. Steyerberg,et al.  Prediction of prostate cancer in unscreened men: external validation of a risk calculator. , 2011, European journal of cancer.

[16]  D. Berney,et al.  Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. , 2010, Cancer research.

[17]  Ziding Feng,et al.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.

[18]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[19]  Sungroh Yoon,et al.  Can the prostate risk calculator based on western population be applied to asian population? , 2012, The Prostate.

[20]  Louis R Kavoussi,et al.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. , 1994, The Journal of urology.

[21]  T. Wu,et al.  The Clinical Usefulness of Prostate-Specific Antigen (PSA) Level and Age-Specific PSA Reference Ranges for Detecting Prostate Cancer in Chinese , 2004, Urologia Internationalis.

[22]  A. Jemal,et al.  Cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[23]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[24]  H. Yamanaka,et al.  Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less. , 2001, Urology.

[25]  Michael W Kattan,et al.  Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. , 2010, The Journal of urology.

[26]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[27]  M. Kuwahara,et al.  Mass screening of prostate cancer in a Chinese population: the relationship between pathological features of prostate cancer and serum prostate specific antigen. , 2005, Asian journal of andrology.

[28]  J. Fraumeni,et al.  Risk of prostate cancer and family history of cancer: a population-based study in China , 2005, Prostate Cancer and Prostatic Diseases.

[29]  M. Plummer,et al.  International agency for research on cancer. , 2020, Archives of pathology.

[30]  M. Roobol,et al.  Prostate carcinoma detection and increased prostate‐specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening , 2005, Cancer.

[31]  Javier Hernandez,et al.  External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. , 2006, Urology.

[32]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[33]  W. Isaacs,et al.  Explaining racial differences in prostate cancer in the United States: Sociology or biology? , 2005, The Prostate.